Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Nov 1;100(9):2170–2181. doi: 10.1172/JCI119753

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

K M Argraves 1, K F Kozarsky 1, J T Fallon 1, P C Harpel 1, D K Strickland 1
PMCID: PMC508411  PMID: 9410893

Abstract

Lp(a) is a major inherited risk factor associated with premature heart disease and stroke. The mechanism of Lp(a) atherogenicity has not been elucidated, but likely involves both its ability to influence plasminogen activation as well as its atherogenic potential as a lipoprotein particle after receptor-mediated uptake. We demonstrate that fibroblasts expressing the human VLDL receptor can mediate endocytosis of Lp(a), leading to its degradation within lysosomes. In contrast, fibroblasts deficient in this receptor are not effective in catabolizing Lp(a). Lp(a) degradation was prevented by antibodies against the VLDL receptor, and by RAP, an antagonist of ligand binding to the VLDL receptor. Catabolism of Lp(a) was inhibited by apolipoprotein(a), but not by LDL or by monoclonal antibodies against apoB100 that block LDL binding to the LDL receptor, indicating that apolipoprotein(a) mediates Lp(a) binding to this receptor. Removal of Lp(a) antigen from the mouse circulation was delayed in mice deficient in the VLDL receptor when compared with control mice, indicating that the VLDL receptor may play an important role in Lp(a) catabolism in vivo. We also demonstrate the expression of the VLDL receptor in macrophages present in human atherosclerotic lesions. The ability of the VLDL receptor to mediate endocytosis of Lp(a) could lead to cellular accumulation of lipid within macrophages, and may represent a molecular basis for the atherogenic effects of Lp(a).

Full Text

The Full Text of this article is available as a PDF (397.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Argraves K. M., Battey F. D., MacCalman C. D., McCrae K. R., Gåfvels M., Kozarsky K. F., Chappell D. A., Strauss J. F., 3rd, Strickland D. K. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem. 1995 Nov 3;270(44):26550–26557. doi: 10.1074/jbc.270.44.26550. [DOI] [PubMed] [Google Scholar]
  2. Battey F. D., Gåfvels M. E., FitzGerald D. J., Argraves W. S., Chappell D. A., Strauss J. F., 3rd, Strickland D. K. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J Biol Chem. 1994 Sep 16;269(37):23268–23273. [PubMed] [Google Scholar]
  3. Becker T. C., Noel R. J., Coats W. S., Gómez-Foix A. M., Alam T., Gerard R. D., Newgard C. B. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 1994;43(Pt A):161–189. doi: 10.1016/s0091-679x(08)60603-2. [DOI] [PubMed] [Google Scholar]
  4. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  5. Bostom A. G., Cupples L. A., Jenner J. L., Ordovas J. M., Seman L. J., Wilson P. W., Schaefer E. J., Castelli W. P. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996 Aug 21;276(7):544–548. doi: 10.1001/jama.1996.03540070040028. [DOI] [PubMed] [Google Scholar]
  6. Bottalico L. A., Keesler G. A., Fless G. M., Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem. 1993 Apr 25;268(12):8569–8573. [PubMed] [Google Scholar]
  7. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  8. Brown M. S., Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47. doi: 10.1126/science.3513311. [DOI] [PubMed] [Google Scholar]
  9. Brown M. S., Goldstein J. L. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987 Nov 12;330(6144):113–114. doi: 10.1038/330113a0. [DOI] [PubMed] [Google Scholar]
  10. Chappell D. A., Fry G. L., Waknitz M. A., Iverius P. H., Williams S. E., Strickland D. K. The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase. J Biol Chem. 1992 Dec 25;267(36):25764–25767. [PubMed] [Google Scholar]
  11. Edelstein C., Mandala M., Pfaffinger D., Scanu A. M. Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry. 1995 Dec 19;34(50):16483–16492. doi: 10.1021/bi00050a032. [DOI] [PubMed] [Google Scholar]
  12. Forsayeth J. R., Garcia P. D. Adenovirus-mediated transfection of cultured cells. Biotechniques. 1994 Aug;17(2):354-6, 357-8. [PubMed] [Google Scholar]
  13. Frykman P. K., Brown M. S., Yamamoto T., Goldstein J. L., Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8453–8457. doi: 10.1073/pnas.92.18.8453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gaw A., Hobbs H. H. Molecular genetics of lipoprotein (a): new pieces to the puzzle. Curr Opin Lipidol. 1994 Apr;5(2):149–155. doi: 10.1097/00041433-199404000-00012. [DOI] [PubMed] [Google Scholar]
  15. Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460–462. doi: 10.1038/370460a0. [DOI] [PubMed] [Google Scholar]
  16. Gåfvels M. E., Caird M., Britt D., Jackson C. L., Patterson D., Strauss J. F., 3rd Cloning of a cDNA encoding a putative human very low density lipoprotein/apolipoprotein E receptor and assignment of the gene to chromosome 9pter-p23. Somat Cell Mol Genet. 1993 Nov;19(6):557–569. doi: 10.1007/BF01233382. [DOI] [PubMed] [Google Scholar]
  17. Gåfvels M. E., Paavola L. G., Boyd C. O., Nolan P. M., Wittmaack F., Chawla A., Lazar M. A., Bucan M., Angelin B. O., Strauss J. F., 3rd Cloning of a complementary deoxyribonucleic acid encoding the murine homolog of the very low density lipoprotein/apolipoprotein-E receptor: expression pattern and assignment of the gene to mouse chromosome 19. Endocrinology. 1994 Jul;135(1):387–394. doi: 10.1210/endo.135.1.8013374. [DOI] [PubMed] [Google Scholar]
  18. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  19. Harpel P. C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest. 1981 Jul;68(1):46–55. doi: 10.1172/JCI110253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harpel P. C., Gordon B. R., Parker T. S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989 May;86(10):3847–3851. doi: 10.1073/pnas.86.10.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Heegaard C. W., Simonsen A. C., Oka K., Kjøller L., Christensen A., Madsen B., Ellgaard L., Chan L., Andreasen P. A. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem. 1995 Sep 1;270(35):20855–20861. doi: 10.1074/jbc.270.35.20855. [DOI] [PubMed] [Google Scholar]
  22. Hofmann S. L., Eaton D. L., Brown M. S., McConathy W. J., Goldstein J. L., Hammer R. E. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990 May;85(5):1542–1547. doi: 10.1172/JCI114602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ishibashi T., Yokoyama K., Shindo J., Hamazaki Y., Endo Y., Sato T., Takahashi S., Kawarabayasi Y., Shiomi M., Yamamoto T. Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. Arterioscler Thromb. 1994 Oct;14(10):1534–1541. doi: 10.1161/01.atv.14.10.1534. [DOI] [PubMed] [Google Scholar]
  24. Jamieson D. G., Usher D. C., Rader D. J., Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol. 1995 Dec;147(6):1567–1574. [PMC free article] [PubMed] [Google Scholar]
  25. Jokinen E. V., Landschulz K. T., Wyne K. L., Ho Y. K., Frykman P. K., Hobbs H. H. Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle. J Biol Chem. 1994 Oct 21;269(42):26411–26418. [PubMed] [Google Scholar]
  26. Kojima S., Harpel P. C., Rifkin D. B. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 1991 Jun;113(6):1439–1445. doi: 10.1083/jcb.113.6.1439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kounnas M. Z., Argraves W. S., Strickland D. K. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. J Biol Chem. 1992 Oct 15;267(29):21162–21166. [PubMed] [Google Scholar]
  28. Kounnas M. Z., Moir R. D., Rebeck G. W., Bush A. I., Argraves W. S., Tanzi R. E., Hyman B. T., Strickland D. K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995 Jul 28;82(2):331–340. doi: 10.1016/0092-8674(95)90320-8. [DOI] [PubMed] [Google Scholar]
  29. Kounnas M. Z., Morris R. E., Thompson M. R., FitzGerald D. J., Strickland D. K., Saelinger C. B. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem. 1992 Jun 25;267(18):12420–12423. [PubMed] [Google Scholar]
  30. Kozarsky K. F., Jooss K., Donahee M., Strauss J. F., 3rd, Wilson J. M. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet. 1996 May;13(1):54–62. doi: 10.1038/ng0596-54. [DOI] [PubMed] [Google Scholar]
  31. Krieger M., Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 1994;63:601–637. doi: 10.1146/annurev.bi.63.070194.003125. [DOI] [PubMed] [Google Scholar]
  32. Lackner C., Cohen J. C., Hobbs H. H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993 Jul;2(7):933–940. doi: 10.1093/hmg/2.7.933. [DOI] [PubMed] [Google Scholar]
  33. Lawn R. M., Wade D. P., Hammer R. E., Chiesa G., Verstuyft J. G., Rubin E. M. Atherogenesis in transgenic mice expressing human apolipoprotein(a) Nature. 1992 Dec 17;360(6405):670–672. doi: 10.1038/360670a0. [DOI] [PubMed] [Google Scholar]
  34. Marcovina S. M., Albers J. J., Gabel B., Koschinsky M. L., Gaur V. P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995 Feb;41(2):246–255. [PubMed] [Google Scholar]
  35. Marcovina S. M., Hobbs H. H., Albers J. J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996 Mar;42(3):436–439. [PubMed] [Google Scholar]
  36. Masuzaki H., Jingami H., Yamamoto T., Nakao K. Effects of estradiol on very low density lipoprotein receptor mRNA levels in rabbit heart. FEBS Lett. 1994 Jun 27;347(2-3):211–214. doi: 10.1016/0014-5793(94)00546-x. [DOI] [PubMed] [Google Scholar]
  37. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  38. Medh J. D., Fry G. L., Bowen S. L., Pladet M. W., Strickland D. K., Chappell D. A. The 39-kDa receptor-associated protein modulates lipoprotein catabolism by binding to LDL receptors. J Biol Chem. 1995 Jan 13;270(2):536–540. doi: 10.1074/jbc.270.2.536. [DOI] [PubMed] [Google Scholar]
  39. Mikhailenko I., Krylov D., Argraves K. M., Roberts D. D., Liau G., Strickland D. K. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem. 1997 Mar 7;272(10):6784–6791. doi: 10.1074/jbc.272.10.6784. [DOI] [PubMed] [Google Scholar]
  40. Miles L. A., Fless G. M., Levin E. G., Scanu A. M., Plow E. F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989 May 25;339(6222):301–303. doi: 10.1038/339301a0. [DOI] [PubMed] [Google Scholar]
  41. Milne R. W., Theolis R., Jr, Verdery R. B., Marcel Y. L. Characterization of monoclonal antibodies against human low density lipoprotein. Arteriosclerosis. 1983 Jan-Feb;3(1):23–30. doi: 10.1161/01.atv.3.1.23. [DOI] [PubMed] [Google Scholar]
  42. Moestrup S. K. The alpha 2-macroglobulin receptor and epithelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands. Biochim Biophys Acta. 1994 Jun 29;1197(2):197–213. doi: 10.1016/0304-4157(94)90005-1. [DOI] [PubMed] [Google Scholar]
  43. Mooser V., Seabra M. C., Abedin M., Landschulz K. T., Marcovina S., Hobbs H. H. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest. 1996 Feb 1;97(3):858–864. doi: 10.1172/JCI118487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Multhaupt H. A., Gåfvels M. E., Kariko K., Jin H., Arenas-Elliot C., Goldman B. I., Strauss J. F., 3rd, Angelin B., Warhol M. J., McCrae K. R. Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry. Am J Pathol. 1996 Jun;148(6):1985–1997. [PMC free article] [PubMed] [Google Scholar]
  45. März W., Beckmann A., Scharnagl H., Siekmeier R., Mondorf U., Held I., Schneider W., Preissner K. T., Curtiss L. K., Gross W. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett. 1993 Jul 5;325(3):271–275. doi: 10.1016/0014-5793(93)81087-g. [DOI] [PubMed] [Google Scholar]
  46. Orlando R. A., Kerjaschki D., Kurihara H., Biemesderfer D., Farquhar M. G. gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6698–6702. doi: 10.1073/pnas.89.15.6698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rader D. J., Mann W. A., Cain W., Kraft H. G., Usher D., Zech L. A., Hoeg J. M., Davignon J., Lupien P., Grossman M. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995 Mar;95(3):1403–1408. doi: 10.1172/JCI117794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H. J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 Sep-Oct;9(5):579–592. doi: 10.1161/01.atv.9.5.579. [DOI] [PubMed] [Google Scholar]
  49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  50. Sakai J., Hoshino A., Takahashi S., Miura Y., Ishii H., Suzuki H., Kawarabayasi Y., Yamamoto T. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem. 1994 Jan 21;269(3):2173–2182. [PubMed] [Google Scholar]
  51. Schaefer E. J., Lamon-Fava S., Jenner J. L., McNamara J. R., Ordovas J. M., Davis C. E., Abolafia J. M., Lippel K., Levy R. I. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994 Apr 6;271(13):999–1003. doi: 10.1001/jama.1994.03510370051031. [DOI] [PubMed] [Google Scholar]
  52. Simonsen A. C., Heegaard C. W., Rasmussen L. K., Ellgaard L., Kjøller L., Christensen A., Etzerodt M., Andreasen P. A. Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein. FEBS Lett. 1994 Nov 14;354(3):279–283. doi: 10.1016/0014-5793(94)01138-9. [DOI] [PubMed] [Google Scholar]
  53. Snyder M. L., Polacek D., Scanu A. M., Fless G. M. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem. 1992 Jan 5;267(1):339–346. [PubMed] [Google Scholar]
  54. Stefansson S., Chappell D. A., Argraves K. M., Strickland D. K., Argraves W. S. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J Biol Chem. 1995 Aug 18;270(33):19417–19421. doi: 10.1074/jbc.270.33.19417. [DOI] [PubMed] [Google Scholar]
  55. Strickland D. K., Kounnas M. Z., Argraves W. S. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J. 1995 Jul;9(10):890–898. doi: 10.1096/fasebj.9.10.7615159. [DOI] [PubMed] [Google Scholar]
  56. Suzuki J., Takahashi S., Oida K., Shimada A., Kohno M., Tamai T., Miyabo S., Yamamoto T., Nakai T. Lipid accumulation and foam cell formation in Chinese hamster ovary cells overexpressing very low density lipoprotein receptor. Biochem Biophys Res Commun. 1995 Jan 26;206(3):835–842. doi: 10.1006/bbrc.1995.1119. [DOI] [PubMed] [Google Scholar]
  57. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252–9256. doi: 10.1073/pnas.89.19.9252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Utermann G., Menzel H. J., Kraft H. G., Duba H. C., Kemmler H. G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987 Aug;80(2):458–465. doi: 10.1172/JCI113093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  60. Webb J. C., Patel D. D., Jones M. D., Knight B. L., Soutar A. K. Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA. Hum Mol Genet. 1994 Apr;3(4):531–537. doi: 10.1093/hmg/3.4.531. [DOI] [PubMed] [Google Scholar]
  61. Williams S. E., Ashcom J. D., Argraves W. S., Strickland D. K. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem. 1992 May 5;267(13):9035–9040. [PubMed] [Google Scholar]
  62. Willnow T. E., Herz J. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands. J Cell Sci. 1994 Mar;107(Pt 3):719–726. [PubMed] [Google Scholar]
  63. Wittmaack F. M., Gåfvels M. E., Bronner M., Matsuo H., McCrae K. R., Tomaszewski J. E., Robinson S. L., Strickland D. K., Strauss J. F., 3rd Localization and regulation of the human very low density lipoprotein/apolipoprotein-E receptor: trophoblast expression predicts a role for the receptor in placental lipid transport. Endocrinology. 1995 Jan;136(1):340–348. doi: 10.1210/endo.136.1.7828550. [DOI] [PubMed] [Google Scholar]
  64. Wyne K. L., Pathak K., Seabra M. C., Hobbs H. H. Expression of the VLDL receptor in endothelial cells. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):407–415. doi: 10.1161/01.atv.16.3.407. [DOI] [PubMed] [Google Scholar]
  65. Zioncheck T. F., Powell L. M., Rice G. C., Eaton D. L., Lawn R. M. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest. 1991 Mar;87(3):767–771. doi: 10.1172/JCI115079. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES